Only 154 companies in the new version of GMP passed the certification or were eliminated

On the 20th, the State Food and Drug Administration's 2012 working meeting, Shao Mingli, director of the Food and Drug Administration, disclosed that as of now, 154 drug manufacturers have passed the new version of the GMP certification inspection, "regulatory departments at all levels must be 'zero tolerance' Attitudes implement a new version of GMP,” said Chen Min, Minister of Health at the conference.

With the development of domestic pharmaceutical companies and the health industry, in 2010, the relevant departments and various experts revised the “outdated” 98 version of GMP.

Chen Hao said that in the future, the State Food and Drug Administration and the drug administration departments should fully implement electronic supervision of essential drugs, establish a dynamic tracking system, and strictly carry out quality supervision of essential drugs.

It is understood that the newly revised pharmaceutical GMP is a major measure to protect advanced productivity, eliminate backward productive forces, promote industrial restructuring, and enhance the international competitiveness of China's pharmaceutical industry. It will have a major impact on pharmaceutical companies and industrial structure because of the inability of the pharmaceutical industry to pass through. Must stop production or change production.

However, related parties did not disclose how many companies would stop production and switch production. It is also understood that there are currently about 5,000 domestic pharmaceutical companies.

Earlier, Premier Wen Jiabao of the State Council presided over the State Council Executive Meeting on December 7 to discuss and approve the National Drug Safety Plan (2011-2015), which proposes that the pharmaceutical production in 2015 be 100% in line with the newly revised "Pharmaceutical Production." “Quality Management Rules” requirements, and pointed out that a long-term mechanism for the supervision of drug safety should be established. The system for the recall and disposal of problem drugs and delisting drugs should be improved. The credit rating of pharmaceutical enterprises should be evaluated, and the enterprise integrity records should be established. The industry should be banned from serious violations and untrustworthy persons. Into. (Reporter Wen Shuping)